Cassava Sciences, Inc. (SAVA)

$ 102.22
-31.95 (-23.61%)
-
Symbol SAVA
Price $ 102.22
Beta 1.120
Volume Avg. 2.68M
Market Cap 4.13B
Shares () -
52 Week Range 2.78-146.06
1y Target Est -
DCF Unlevered -
DCF Levered -
ROE -11.79% Sell
ROA -4.37% Neutral
Operating Margin -
Debt / Equity 1.02% Neutral
P/E -
P/B 13.86 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

About


Mr. Remi Barbier
Healthcare
Biotechnology
Nasdaq Capital Market

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for nervous system disorders. Its lead therapeutic product candidate is PTI-125, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was founded in 1998 and is based in Austin, Texas.